RRR

RHYTHM BIOSCIENCES LIMITED

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪30.55 M‬AUD
−0.030AUD
‪−6.86 M‬AUD
0.00AUD
‪172.89 M‬
Beta (1Y)
2.53

About RHYTHM BIOSCIENCES LIMITED


CEO
David George Atkins
Headquarters
Parkville
Founded
2017
ISIN
AU000000RHY2
FIGI
BBG00HZRNTL2
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. It offers a diagnostic blood test for screening for colorectal cancer under the ColoSTAT brand. The company was founded on June 1, 2017, and is headquartered in Parkville, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RHY is 0.120 AUD — it has increased by 7.69% in the past 24 hours. Watch RHYTHM BIOSCIENCES LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange RHYTHM BIOSCIENCES LIMITED stocks are traded under the ticker RHY.
RHY stock has risen by 12.00% compared to the previous week, the month change is a 33.33% rise, over the last year RHYTHM BIOSCIENCES LIMITED has showed a −31.90% decrease.
RHY reached its all-time high on Nov 8, 2021 with the price of 2.035 AUD, and its all-time low was 0.035 AUD and was reached on Mar 24, 2020. View more price dynamics on RHY chart.
See other stocks reaching their highest and lowest prices.
RHY stock is 16.67% volatile and has beta coefficient of 2.53. Track RHYTHM BIOSCIENCES LIMITED stock price on the chart and check out the list of the most volatile stocks — is RHYTHM BIOSCIENCES LIMITED there?
Today RHYTHM BIOSCIENCES LIMITED has the market capitalization of ‪32.84 M‬, it has increased by 13.94% over the last week.
Yes, you can track RHYTHM BIOSCIENCES LIMITED financials in yearly and quarterly reports right on TradingView.
RHYTHM BIOSCIENCES LIMITED is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
RHY net income for the last half-year is ‪−2.77 M‬ AUD, while the previous report showed ‪−4.09 M‬ AUD of net income which accounts for 32.41% change. Track more RHYTHM BIOSCIENCES LIMITED financial stats to get the full picture.
No, RHY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RHY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade RHYTHM BIOSCIENCES LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So RHYTHM BIOSCIENCES LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating RHYTHM BIOSCIENCES LIMITED stock shows the neutral signal. See more of RHYTHM BIOSCIENCES LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.